

## Core Issue I : Individual or Group Consent

Figure III: The Ideology of Group Consent.






Figure IV Group Consent Process




生物銀行  
立法建議


## Core Issue II: Information Asymmetry




生物銀行  
 立法討論

## Core Issue III: Aboriginal People's Participation



- 
- It takes more than 2 years before IRB may reach conclusion
  - All the ELSI works turn out to be on the paper-based review, which cannot be substantiated.
  - ELSI section, as a part of the research project, was taken as an guardian to the bio section. (Conflict of Interest)
  - Human right group insisted on the completion of legislation
  - Reaching the end of Pilot Project, the result belonging, operation framework, the implementation of public goals, who should be held responsible for the project driving and how to promote the benefit sharing are all in issue.



## Solutions Admitted by IRB at the End of 2008

## Approval of Experimental Tissue Collection

- 以IRB既有的附條件同意為基礎，以期限及檢體採集數量的雙門檻為限，在IRB確認的程序下，在目前人員訓練及設備均較為成熟的駐站實施試行收案。
- IRB負責全程監督，並由既有ELSI人員協力，一旦有所疑慮則可隨時停止試行。
- 以此試行經驗作為未來EGC的監理基礎，以免EGC委員必須再重複紙上審理程序，並可提供公眾溝通的具體事證，減少假設性爭議。

## Accelerating the EGC Establishment

- EGC顯為當前各方認為具獨立性，而較能為社會信任的倫理治理機構，也是本計劃倫理治理規範及管理條例(草案)所要求設置者，應加速其建置。
- 惟一般的期待往往與現實有間，蓋我國的Biobank仍處研究計劃階段，實際上應以執行單位之IRB為倫理治理單位為是；為避免EGC成立後與IRB之分際混淆，建議EGC的設置應配合後述籌備處的設計，使之成為籌備處的獨立監理單位，真正擁有制度化的法律地位；並有別於原研究計劃的IRB。

## Perfect the Legislation Work

- 人權團體與部份立委在此方面的期待已嚴重影響計劃的推動經費與時程，如何加速立法進程，攸關未來本計劃的能否續行；應優先推動。
- 執行上應有政府與產官學研的密切合作；以過去落實科技會議決議的法規調適經驗來推動有其必要。

## Transform into an Legal Entity

- 將研究成果與採集的檢體交由制度化的籌備處負責管理，將能解決前述IRB與EGC的重疊問題必強化倫理治理機制的獨立性與可信賴性。
- 以具法律地位的籌備處來接手，將能區隔原計劃與執行單位間的法律關係，使參與者之權利義務更清楚，並在某種程度上受到現有法律的監督，有利於滿足社會所期待公共利益的落實。
- 以籌備處名義作業有利於Biobank制度化的先期運作經驗的累積、營運人才的養成以及後續營運模式的確立。

## A Sketch on Auditing Report

### 1. Abstract

- 1.1 The Project Purposes
- 1.2 The Review on Designed Tissue Collection Process
- 1.3 Checking Points
- 1.4 Compliance with Related Rules
- 1.5 Conclusion




## 2. The Recruitment of Participants

- 2.1 Targeting & Acquisition of Participants' Contact Information
- 2.2 The management of Recruitment Operation
- 2.3 Q & A and Information Flow
- 2.4 Cooperative Medical Institutes' Questions and Responses
- 2.5 An Analysis on Reason of Participants' Refusal

## 3. Interview Conducted by Collection Sites

- 3.1 Collection Sites' Facilities and Related Arrangements
- 3.2 Contents & Time Schedule of Interview
- 3.3 Participant's Recognition & Opinion




## 4. Management Proceeding Collected Tissues and Personal Data

- 4.1 Establishment of Headquarter & Collection Sites
  - 4.2 Transportation & Management of Collected Tissues & Personal Data
- 



## 5. Collateral Documents


- Including All Forms, SOP Guidance, Protocol, and etc.
- 



## Major Faults The Auditing Found So Far


1. Dispute Settlement Mechanism is Wanting
2. SOPs Were Not Certified by ELSI Division
3. Collection Site was not Affiliated with ELSI Staff
4. No Record in Keeping Public Consultation and Responses
5. Lacking of A Comprehensive Auditing Scheme
6. Lacking of Concrete Operation Plan
7. Privacy Protection & Encryption Key Keeping Design are Incomplete
8. Data Access Rules are Premature & in Conflict with Ethical Governance Implementation Guidance
9. Transportation Arrangement is not Secured Fairly
10. A Possible Hiding of Some Other Research Projects
11. Decryption Procedure need be Further Certified by ELSI Review

## Possible Corrective Efforts

## Enhancing the Cooperation between BIO & ELSI Disciplines







生物銀行  
立法諮詢

Thank you for your attention

**International Symposium  
Biobank and Genomic Research  
- Bioethics of Genomic Medicine**

***Ethics, Law and Governance of  
Biobanks***

**Professor Don Chalmers**

**KYOTO, 22 March 2009**



## Overview

- Biobanks – Definition
- Biobanks – National and International
- Biobanks and Genomic science
- Research uses and Personalised medicine
- Technical challenges for Biobanks
- Legal and Ethical challenges for Biobanks
- Governance Principles
- Conclusions

## 1 Biobanks - Definitions

- Biobanks are specifically created collections of human tissue samples established with the specific aim of conducting **research**.
- UK “Biobank”; Latvia - “genebank”; French National Ethics Consultative Committee - “biolibraries”

## 1 Biobanks -Existing Collections?

- ♦ Existing collections of human tissue (eg Pathology samples; blood banks) with **primary** aim for diagnostic and clinical purposes
- These collections may be used for **secondary** purpose of research
- Are these Biobanks? Generally no but may be organised with proper governance arrangements.
- Existing collections have only specific and limited consent regimes.



## 2 Biobanks- National

- *National* UK Biobank (**500,000**) DeCode (Iceland); Estonian Genome; Karolinska Institutet (Sweden); CARTaGENE (Quebec); GenomEUtwin (Finland); Danubian Biobank Foundation (six countries in Central Europe); KORA-GEN (Germany); LifeGene (Sweden); **Generation Scotland**; INMEGEN (Mexico); LifeLines (Netherlands); National Heart, Lung and Blood Institute (NIH USA); Centre for Integrated Genomic Medical Research (UK).
- Japan and Taiwan
- *Australia*: WA Genetic Health project (Busselton); Victoria cancer consortium; Tasmania Menzies Centre

## 2 Biobanks: International

- *International Haplotype Mapping Project*: USA, UK, Japan, Nigeria, China and Canada collaboration after Human Genome Project to study/find genes that affect health, disease and medication responses
- *Public Population Project in Genomics (P3G)*; genome Canada not-for-profit public database for biobank/genomics community, (motto - *transparency and collaboration*)- Consent forms; Guidelines; P3G Observatory; 22 Charter; 13 Associate; 152 members (41 countries, **10.5 million participants**)
- PHOEBE (Promotion and Harmonization of Epidemiological Biobanks in Europe)
- Translational Genomic Research in the African Diaspora (TgRIAD)

### 3 Biobanks and Genomic Science

- Francis Collins NHGRI “The Genome Era”
- Exponential increase in 2007 in information about genes implicated in complex genetic disorders.
- New paradigms are emerging how genes and gene-gene interactions (e.g. networks in obesity) might function.
- New analytic research platforms allow multi-centre collaborative “blockbuster” type association studies to identify even more about gene activity

### 3 Biobanks and Genomic Science

#### Confirmed genetic contributors to common human diseases (Sept 2007)

Disease	Gene	Chromosome	Year
Cholesterol	LDLR	16q25.1	2001
Obesity	FTO	16q24.3	2007
Coronary Disease	9p21	9p21	2007
QT interval	KCNJ11	11p15.5	2001
Atrial Fibrillation	KCNQ1	3q21	2001
Type 2 Diabetes	TCF7L2	10q25.3	2005
Prostate cancer	HOXB13	17q21.31	2007
Breast cancer	BRCA1	17q21.31	1990
Colon cancer	5p21	5p21	2007
Age-Related Macular Degeneration	CFE1	10q26	2005
Crohn's Disease	NOD2	16q22.1	2001
Type 1 Diabetes	INS	11p15.5	1974
Systemic Lupus Erythematosus	IRF5	9q24.33	2007
Asthma	IL13	5q31	2007
Restless leg syndrome	MEIS1	12p12.1	2007
Gallstone disease	IL12B	7p14.3	2007
Multiple sclerosis	IL28B	10q26.3	2009
Rheumatoid arthritis	PTEN2	9q34	2007
Glaucoma	TCF2	11p15.5	2007
	CDKN2B	12q24.1	2007
	IGFBP3	12q24.1	2007
	CDKAL1	12q24.1	2007
	HHEX	12q24.1	2007
	SLC30A8	8q24	2007
	IRF5	9q24.33	2007
	PCSK9	16q22.1	2007
	IL28R	10q26.3	2009
	C22orf1	22q13.1	2007
	TCF7L2	10q25.3	2005
	MEIS1	12p12.1	2007
	CDKN2A	12q24.1	2007
	LRXCOR	1	2007
	BTBD9	17q21.31	2007
	TCF2	11p15.5	2007
	8q24	8q24	2007
	ORMDL3	4q25	2007
	4q25	4q25	2007
	TCF2	11p15.5	2007
	GCKR	10q26	2007
	FTO	16q24.3	2007
	IL7R	11p15.5	2007
	TRAF1	10q26.3	2007
	STAT4	2q37.3	2007
	ABCG8	2q37.3	2007
	GALNT2	10q26.3	2007
	PSRC1	9q34	2007
	NCAN	11p15.5	2007
	TBL2	12q24.1	2007
	TRIB1	12q24.1	2007
	KCTD18	12q24.1	2007
	ANGPT1	11p15.5	2007
	GRIN1A	8q24	2007

Dr E Zarhoum (NH) presentation 30 Jan 2008

### 3 Biobanks and Genomic Science

- ❑ Example of blockbuster study: breast cancer susceptibility genome-wide association study involving 28 centres in 12 countries and 50,000 samples
- ❑ 'The detection of further loci will require....larger numbers of cases and controls...[and] results across multiple studies'(Easton)-from *individual* to *population*

### 3 Biobanks and Genomic Science

- ❑ Taichi Sakaiya – *Knowledge-Value Revolution*
- ❑ Convergence of technologies -HGP and collaborations; computers and bioinformatics; microarrays; new tests; proteomics and metabolomics; national biotechnology policies; increased funding (eg President Obama in USA \$20 billion); Commercialisation and Partnerships

### 3 Biobanks and Genomic Science

**GEN** Genetic Engineering & biotechnology News  
*Biotechnology from bench to business* Volume 33 Number 11 November 1, 2005

**Pushing Toward a \$1,000 Genome**  
 Stepwise Technological Evolution Will Continue, but Disruptive Spurts Are Also Forecast

**DRUG DISCOVERY**  
 22 Fragment Based Discovery in Spotlight

**BIOPROCESSING**  
 22 Use of LC-Gel in MS Sample Prep

**GENETIC ENGINEERING**  
 14 Leveraging Impact of Bioinformatics Centers

**TRANSLATIONAL MEDICINE**  
 18 Genetic Engineering: From Bench to Business

**BIOBUSINESS**  
 16 Biotech Startups: A New Wave of Innovation

**LIQUID CHROMATOGRAPHY**  
 10 Liquid Chromatography: A New Wave of Innovation

**PHARMACEUTICALS**  
 12 Pharmaceutical Industry: A New Wave of Innovation

**CELLULAR ENGINEERING**  
 14 Cellular Engineering: A New Wave of Innovation

**BIOMATERIALS**  
 16 Biomaterials: A New Wave of Innovation

**BIOTECHNOLOGY**  
 18 Biotechnology: A New Wave of Innovation

**GENETIC ENGINEERING**  
 20 Genetic Engineering: A New Wave of Innovation

**BIOPROCESSING**  
 22 Bioprocessing: A New Wave of Innovation

**BIOBUSINESS**  
 24 BioBusiness: A New Wave of Innovation

### 4 Research Uses of Biobanks

- Large scale research and biobanks and rising health costs (cancer, diabetes, heart disease).
- Large scale genetic epidemiology studies; Disease gene/proteomic discovery studies
- “Biobanks are increasingly seen as an essential tool in translating biomedical research into real improvements in healthcare” (*Genetic Engineering News*, 2005)